ArticleThe Journal of clinical endocrinology and metabolism2024
Approach to the Patient: Insulinoma.
Article in The Journal of clinical endocrinology and metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Endoscopic ultrasound-guided radiofrequency ablation of pancreatic insulinoma.Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2026Pooled it
- Ersodetug for refractory hypoglycemia due to malignant insulin-secreting tumors.The Journal of clinical endocrinology and metabolism · 2026Article
- Glucagon-like peptide-1 receptor PET in indolent and aggressive insulinoma: Diagnostic performance, quantitative differences, and clinical implications.European journal of nuclear medicine and molecular imaging · 2026Article
- Shades of insulinoma one century after first extensive evaluation by Wilder and colleagues; a figurative review between light and dark.Reviews in endocrine & metabolic disorders · 2026Review
- Procedure-specific morbidity and pathologic assessment after resection of small (≤20 mm) pancreatic neuroendocrine tumors.Journal of neuroendocrinology · 2026Observational
- Iatrogenic Dextrose Hyperosmolar Extravasation Injury in Suspected Endogenous Hyperinsulinism.Cureus · 2026Article
- Bilateral Ballismus: An Unusual Clinical Sign With an Unexpected Origin.Clinical case reports · 2026Article
- Occult Insulinoma: A 19-Year Diagnostic Delay in a Patient With Recurrent Hypoglycemia.Cureus · 2026Article
- Clinical Presentation and Outcomes of Insulinomas in Pediatric Patients.Hormone research in paediatrics · 2026Article
- Decreasing Hemoglobin A1c: Progress or Pathology?Cureus · 2026Article
- Clinical outcomes of medical therapy, EUS-guided ethanol ablation, and surgical resection in insulinoma: a clinical epidemiology study.Frontiers in endocrinology · 2026Article
- Unspecific clinical manifestations of insulinoma found in preoperative testing: a case report and narrative review.Frontiers in endocrinology · 2026Review
- Unmasking an insulinoma: recurrent Hypoglycemia in a young patient following GLP-1 receptor agonist therapy -A case report.Oxford medical case reports · 2026Article
- Persistent Hyperinsulinemic Hypoglycemia After Insulinoma Surgery: Diagnostic Impact of GLP-1 Receptor PET/CT After Negative Conventional Imaging.Case reports in endocrinology · 2026Article
- From companion animals to patients: interspecies lessons in neuroendocrine oncology.Frontiers in veterinary science · 2026Review
- Early prediction of metastatic insulinoma using tumor size and biochemical markers: a retrospective cohort study.Frontiers in endocrinology · 2026Article
- Insulin Resistance/Hyperinsulinemia Should Be Considered in the Prevention and Treatment of Essential Hypertension.Biomedicines · 2025Article
- Current Medical Controversies in Zollinger-Ellison Syndrome.Biomedicines · 2025Review
- From diagnosis to treatment: navigating the course for pancreatic neuroendocrine neoplasms.Annals of medicine · 2025Review
- Minimally Invasive Resection of Occult Insulinomas-Experience from an ENETS Centre of Excellence and Review of the Literature.Cancers · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insulinomas are hormone-producing pancreatic neuroendocrine neoplasms with an estimated incidence of 1 to 4 cases per million per year. Extrapancreatic insulinomas are extremely rare. Most insulinomas present with the Whipple triad: (1) symptoms, signs, or both consistent with hypoglycemia; (2) a low plasma glucose measured at the time of the symptoms and signs; and (3) relief of symptoms and signs when the glucose is raised to normal. Nonmetastatic insulinomas are nowadays referred to as "indolent" and metastatic insulinomas as "aggressive." The 5-year survival of patients with an indolent insulinoma has been reported to be 94% to 100%; for patients with an aggressive insulinoma, this amounts to 24% to 67%. Five percent to 10% of insulinomas are associated with the multiple endocrine neoplasia type 1 syndrome. Localization of the insulinoma and exclusion or confirmation of metastatic disease by computed tomography is followed by endoscopic ultrasound or magnetic resonance imaging for indolent, localized insulinomas. Glucagon-like peptide 1 receptor positron emission tomography/computed tomography or positron emission tomography/magnetic resonance imaging is a highly sensitive localization technique for seemingly occult, indolent, localized insulinomas. Supportive measures and somatostatin receptor ligands can be used for to control hypoglycemia. For single solitary insulinomas, curative surgical excision remains the treatment of choice. In aggressive malignant cases, debulking procedures, somatostatin receptor ligands, peptide receptor radionuclide therapy, everolimus, sunitinib, and cytotoxic chemotherapy can be valuable options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.